[{"id":"c83f1ca5-f8ac-4ba6-b9aa-01738d1a4ab7","acronym":"KeyVibe-003","url":"https://clinicaltrials.gov/study/NCT04738487","created_at":"2021-02-04T18:58:44.596Z","updated_at":"2024-07-02T16:34:26.003Z","phase":"Phase 3","brief_title":"Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)","source_id_and_acronym":"NCT04738487 - KeyVibe-003","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • PD-L1 • ALK • ROS1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["EGFR • PD-L1 • ALK • ROS1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Recruiting","enrollment":" Enrollment 1246","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 04/21/2026","primary_completion_date":" 04/21/2026","study_txt":" Completion: 06/05/2028","study_completion_date":" 06/05/2028","last_update_posted":"2024-06-14"},{"id":"a64feebf-818b-47cf-b389-052e32de01bb","acronym":"KEYVIBE-001","url":"https://clinicaltrials.gov/study/NCT02964013","created_at":"2021-01-18T14:34:08.380Z","updated_at":"2024-07-02T16:35:08.757Z","phase":"Phase 1","brief_title":"Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)","source_id_and_acronym":"NCT02964013 - KEYVIBE-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • etoposide IV • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 492","initiation":"Initiation: 12/13/2016","start_date":" 12/13/2016","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-18"},{"id":"f19510c6-4f6e-4c4a-acda-e326ec332711","acronym":"KEYVIBE-002","url":"https://clinicaltrials.gov/study/NCT04725188","created_at":"2021-01-26T15:52:24.286Z","updated_at":"2024-07-02T16:35:11.960Z","phase":"Phase 2","brief_title":"Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)","source_id_and_acronym":"NCT04725188 - KEYVIBE-002","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 08/13/2027","study_completion_date":" 08/13/2027","last_update_posted":"2024-04-02"}]